• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?

作者信息

Jacobs Jeremy W, Stephens Laura D, Chooljian David M, Sharma Deva, Adkins Brian D, Booth Garrett S

机构信息

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Department of Pathology, University of California San Diego, La Jolla, California, USA.

出版信息

Am J Hematol. 2024 Jun;99(6):1016-1018. doi: 10.1002/ajh.27275. Epub 2024 Feb 26.

DOI:10.1002/ajh.27275
PMID:38409818
Abstract
摘要

相似文献

1
Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?克立硃单抗与镰状细胞病：药物的批准状态何时应被撤销？
Am J Hematol. 2024 Jun;99(6):1016-1018. doi: 10.1002/ajh.27275. Epub 2024 Feb 26.
2
Crizanlizumab: First Approval.西尼兰单抗：首次获批
Drugs. 2020 Jan;80(1):79-84. doi: 10.1007/s40265-019-01254-2.
3
Two New Drugs for Sickle Cell Disease.两种治疗镰状细胞病的新药。
Am J Nurs. 2020 Mar;120(3):24. doi: 10.1097/01.NAJ.0000656312.23070.38.
4
Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.系统性评价克里扎尼单抗：一种新的注射用药物，可减少镰状细胞病患者血管阻塞性危象疼痛发作
Pharmacotherapy. 2020 Jun;40(6):535-543. doi: 10.1002/phar.2409. Epub 2020 May 20.
5
A critical evaluation of crizanlizumab for the treatment of sickle cell disease.对治疗镰状细胞病的 crizanlizumab 的评价。
Expert Rev Hematol. 2022 Jan;15(1):5-13. doi: 10.1080/17474086.2022.2023007. Epub 2021 Dec 30.
6
Two drugs for sickle cell disease.两种用于治疗镰状细胞病的药物。
Med Lett Drugs Ther. 2020 Apr 6;62(1595):51-52.
7
Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study.镰状细胞病的长期生物学效应：来自crizanlizumab治疗后研究的见解
Br J Haematol. 2021 Nov;195(4):e150-e153. doi: 10.1111/bjh.17739. Epub 2021 Oct 5.
8
Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.镰状细胞病（SCD）患者接受crizanlizumab 治疗时输注相关反应（IRR）管理的专家共识：RAND/UCLA 改良 Delphi 小组。
Ann Hematol. 2024 Jun;103(6):1909-1917. doi: 10.1007/s00277-024-05736-6. Epub 2024 Apr 20.
9
Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease.一名患有镰状细胞病的青少年对crizanlizumab发生严重的输液相关反应。
Am J Hematol. 2020 Dec;95(12):E338-E339. doi: 10.1002/ajh.26002. Epub 2020 Sep 30.
10
Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report.停用 Crizanlizumab 后急性胸部综合征复发：镰状细胞病患者停药与继续用药的困境：病例报告。
Hematology. 2023 Dec;28(1):2229115. doi: 10.1080/16078454.2023.2229115.

引用本文的文献

1
The wider perspective: Barriers and recommendations for transfusion support for patients with sickle cell disease in low- and middle-income countries.更广阔的视角：低收入和中等收入国家镰状细胞病患者输血支持的障碍与建议
Br J Haematol. 2025 Jun;206(6):1585-1592. doi: 10.1111/bjh.20055. Epub 2025 Mar 27.
2
Neuroprotective, anti-inflammatory, and analgesic activity of palmitoylethanolamide in sickle cell mice.棕榈酰乙醇胺在镰状细胞小鼠中的神经保护、抗炎和镇痛活性。
Blood Adv. 2025 Jun 24;9(12):3056-3068. doi: 10.1182/bloodadvances.2024015439.
3
Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy.
免疫格局中的血小板信号传导：综合机制与临床治疗
Biomark Res. 2024 Dec 31;12(1):164. doi: 10.1186/s40364-024-00700-y.
4
Fostering a healthier generation of children with sickle cell disease through advancements in care.通过护理方面的进步，培养出更健康的镰状细胞病患儿一代。
Pediatr Res. 2024 Sep 13. doi: 10.1038/s41390-024-03566-w.
5
Current and Future Therapeutics for Treating Patients with Sickle Cell Disease.治疗镰状细胞病患者的当前和未来疗法。
Cells. 2024 May 16;13(10):848. doi: 10.3390/cells13100848.